Crossmark

Single-cell RNA sequencing of terminal ileal biopsies identifies signatures of Crohn’s disease pathogenesis

Crossref DOI link: https://doi.org/10.1038/s41588-026-02634-7

Published Online: 2026-06-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Krzak, Monika https://orcid.org/0009-0005-4157-7126
Alegbe, Tobi https://orcid.org/0000-0003-1622-0502
Taylor, D. Leland https://orcid.org/0000-0001-6498-6970
Jones, Gareth-Rhys https://orcid.org/0000-0001-7355-2357
Ghouraba, Mennatallah https://orcid.org/0000-0003-4671-3500
Strickland, Michelle https://orcid.org/0000-0001-8053-400X
Harris, Bradley T. https://orcid.org/0000-0001-9585-1016
Satti, Reem

Arestang, Kenneth

Ramirez-Navarro, Lucia https://orcid.org/0000-0003-2194-2438
Nishad, Nilanga

Cheam, Kimberly Ai Xian

Tutert, Marcus

Ozols, Matiss

Noell, Guillaume

Leonard, Steven

Przybilla, Moritz J. https://orcid.org/0000-0001-5645-9492
Suastegui, Ciro Ramirez

Khabirova, Eleonora https://orcid.org/0000-0002-5891-6789
Deng, Tong

Najgebauer, Hanna https://orcid.org/0000-0003-1010-0403
Petrova, Velislava

Jones, Carla P. https://orcid.org/0000-0002-4329-3267
Wana, Noor

Hu, May Xueqi

Skelton, Jason

Ostermayer, Jasmin

Gu, Yong

Garri, Wendy

Brezina, Biljana

Caballes, Charry Queen

Corridoni, Daniele https://orcid.org/0000-0003-0251-2248
Parkes, Miles https://orcid.org/0000-0002-6467-0631
Iyer, Vivek

Martin, Cristina Cotobal https://orcid.org/0000-0002-5877-2228
McIntyre, Rebecca E. https://orcid.org/0000-0001-5291-1533
Raine, Tim https://orcid.org/0000-0002-5855-9873
Anderson, Carl A. https://orcid.org/0000-0003-1719-7009
License Information

Text and Data Mining valid from 2026-06-15

Version of Record valid from 2026-06-15
More Information

Article History

Received: 5 December 2024

Accepted: 8 May 2026

First Online: 15 June 2026

Competing interests

: C.A.A. has received research grants or consultancy or speaker fees from Genomics, BridgeBio, GSK, AstraZeneca and Open Targets. T.R. has received research or educational grants and/or speaker or consultation fees from AbbVie, Arena, Aslan, AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda, UCB and Open Targets. B.T.H. has received speaker fees from BridgeBio. D.C. is now an employee at AstraZeneca. M.T. and R.E.M. are now employees at Relation Therapeutics. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below